Study of Role of Blood Microvescicles and Exosomes in Patients With Graft Occlusion After Aortocoronary Bypass Surgery
MVBYPASS
1 other identifier
observational
300
1 country
1
Brief Summary
Coronary artery bypass graft (CABG) surgery is still the standard treatment of coronary revascularization for patients with severe coronary artery disease (CAD). Graft patency, together with completeness of revascularization, is a major determinant of long-term outcome following CABG. The surgical procedure elicits a persistent systemic inflammatory response associated with the activation of the hemostatic system leading to perturbation of endothelial and vascular function and activation of platelets and leukocytes. All of these events are the main players responsible for the early and late graft failure in a significant percentage of patients.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2022
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 1, 2022
CompletedStudy Start
First participant enrolled
June 1, 2022
CompletedFirst Posted
Study publicly available on registry
June 9, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2025
CompletedAugust 28, 2024
August 1, 2024
3 years
June 1, 2022
August 27, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Confirmation and validation of the potential role of blood MV and exosomes as predictors of bypass occlusions
from 15 to 21 months
Eligibility Criteria
patients undergoing elective CABG ( coronary artery bypass graft )
You may qualify if:
- between the ages of 40 and 80
- Ejection fraction\> 30%
- coronary artery bypass surgery
- informed consent
- Willingness to carry out the follow-up visits and the assessments required by the protocol
You may not qualify if:
- emergency intervention
- changes in liver or kidney function
- changes in coagulation factors
- associated interventions (valve replacement, carotid endarterectomy)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
MCH
Cotignola, Ravenna, 48033, Italy
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
June 1, 2022
First Posted
June 9, 2022
Study Start
June 1, 2022
Primary Completion
June 1, 2025
Study Completion
September 1, 2025
Last Updated
August 28, 2024
Record last verified: 2024-08
Data Sharing
- IPD Sharing
- Will not share